While vitamin D is critical for optimal skeletal health, it also appears to play a significant role in vascular homeostasis. This pilot study compared arteriovenous (AV) access outcomes following cholecalciferol supplementation compared to placebo in end-stage renal disease patients preparing to undergo AV access creation.
Methods
A total of 52 adult hemodialysis patients preparing for arteriovenous fistula (AVF) creation were randomized to receive perioperative high-dose cholecalciferol versus placebo in this double-blind, randomized, placebo-controlled pilot study. The primary outcome was mean response to high-dose oral cholecalciferol versus placebo, and secondary outcome AV access maturation at 6 months. Logistic regression was used to assess the association between AV access maturation and baseline, posttreatment and overall change in vitamin D concentration.
Results
A total of 45% of cholecalciferol-treated and 54% of placebo-treated patients were successfully using their AVF or arteriovenous graft (AVG) at 6 months (p=0.8). Baseline serum concentrations of 25(OH)D and 1,25(OH)2D did not differ between those who experienced AVF or AVG maturation and those who did not (p=0.22 and 0.59, respectively). Similarly, there was no relationship between AVF or AVG maturation and posttreatment serum 25(OH)D and 1,25(OH)2D concentration (p=0.24 and 0.51, respectively).
Conclusions
Perioperative high-dose vitamin D3 therapy does correct 25(OH)D level but does not appear to have an association with AV access maturation rates. Future research may include extended preoperative vitamin D3 therapy in a larger population or in certain subpopulations at high risk for AVF failure.
SaabGYoungDOGinchermanYGilesKNorwoodKCoyneDWPrevalence of vitamin D deficiency and the safety and effectiveness of monthly ergocalciferol in hemodialysis patients. Nephron Clin Pract20071053c132–c138
2.
WolfMShahAGutierrezOVitamin D levels and early mortality among incident hemodialysis patients. Kidney Int20077281004–1013
3.
ZehnderDBlandRWilliamsMCExtrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. J Clin Endocrinol Metab2001862888–894
4.
AdoriniLAmuchasteguiSDanielKCPrevention of chronic allograft rejection by vitamin D receptor agonists. Immunol Lett2005100134–41
5.
KobayashiHAsanoKKanaiKSuzakiHSuppressive activity of vitamin D3 on matrix metalloproteinase production from cholesteatoma keratinocytes in vitro. Mediators Inflamm200520054210–215
6.
TimmsPMMannanNHitmanGACirculating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders?QJM20029512787–796
7.
Wu-WongJRNakaneMMaJEffects of vitamin D analogs on the expression of plasminogen activator inhibitor-1 in human vascular cells. Thromb Res20061186709–714
8.
Ruth Wu-WongJNakaneMMaJCookALVitamin D analogs down-regulate plasminogen activator inhibitor-1 in human coronary artery smooth muscle cells. J Thromb Haemost2005371545–1546
9.
Gouni-BertholdIKroneWBertholdHKVitamin D and cardiovascular disease. Curr Vasc Pharmacol200973414–422
SomjenDWeismanYKohenF25-Hydroxyvitamin D3-1alpha-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation2005111131666–1671
12.
SugdenJADaviesJIWithamMDMorrisADStruthersADVitamin D improves endothelial function in patients with type 2 diabetes mellitus and low vitamin D levels. Diabet Med2008253320–325
13.
FormanJPGiovannucciEHolmesMDPlasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension20074951063–1069
14.
AlvarezJALawJCoakleyKEHigh-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: a pilot, randomized, double-blind, placebo-controlled trial. Am J Clin Nutr2012963672–679
15.
MelamedMLMuntnerPMichosEDSerum 25-hydroxyvitamin D levels and the prevalence of peripheral arterial disease: results from NHANES 2001 to 2004. Arterioscler Thromb Vasc Biol20082861179–1185
16.
ZittermannASchleithoffSSTenderichGBertholdHKKörferRStehlePLow vitamin D status: a contributing factor in the pathogenesis of congestive heart failure?J Am Coll Cardiol2003411105–112
17.
CarthyEPYamashitaWHsuAOoiBS1,25-Dihydroxyvitamin D3 and rat vascular smooth muscle cell growth. Hypertension1989136 Pt 2954–959
18.
Wu-WongJRNakaneMMaJRuanXKroegerPEEffects of vitamin D analogs on gene expression profiling in human coronary artery smooth muscle cells. Atherosclerosis2006186120–28
19.
DeanDDBoyanBDSchwartzZEffect of 1alpha, 25-dihydroxyvitamin D3 and 24R, 25-dihydroxyvitamin D3 on metalloproteinase activity and cell maturation in growth plate cartilage in vivo. Endocrine2001143311–323
20.
ChenSLCGardnerDGVitamin D-dependent suppression of endothelin-induced vascular smooth muscle cell proliferation through inhibition of CDK2 activity. J Steroid Biochem Mol Biol20101183135–141
21.
Wu-WongJRNakaneMMaJVitamin D analogs modulate the expression of plasminogen activator inhibitor-1, thrombospondin-1 and thrombomodulin in human aortic smooth muscle cells. J Vasc Res200744111–18
22.
LinRWhiteJHThe pleiotropic actions of vitamin D. Bioessays200426121–28
23.
LinAMChenKBChaoPLAntioxidative effect of vitamin D3 on zinc-induced oxidative stress in CNS. Ann N Y Acad Sci200510531319–329
24.
SchleithoffSSZittermannATenderichGBertholdHKStehlePKoerferRVitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr2006834754–759
25.
WeissMFScivittaroVAndersonJMOxidative stress and increased expression of growth factors in lesions of failed hemodialysis access. Am J Kidney Dis2001375970–980
26.
MisraSFuAARajanDKExpression of hypoxia inducible factor-1 alpha, macrophage migration inhibition factor, matrix metalloproteinase-2 and -9, and their inhibitors in hemodialysis grafts and arteriovenous fistulas. J Vasc Interv Radiol2008192 Pt 1252–259
27.
MisraSLeeNFuAAIncreased expression of a disintegrin and metalloproteinase thrombospondin 1 in thrombosed hemodialysis grafts. J Vasc Interv Radiol2008191111–119
28.
WasseHHuangRLongQSingapuriSRaggiPTangprichaVEfficacy and safety of a short course of very-high-dose cholecalciferol in hemodialysis. Am J Clin Nutr2012952522–528
29.
Clinical Practice Guidelines for Vascular Access. Am J Kidney Dis200648S176–273
30.
HolickMFBinkleyNCBischoff-FerrariHAEndocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab20119671911–1930
31.
ZehnderDBlandRChanaRSSynthesis of 1, 25-dihydroxyvitamin D(3) by human endothelial cells is regulated by inflammatory cytokines: a novel autocrine determinant of vascular cell adhesion. J Am Soc Nephrol2002133621–629
32.
GuptaGKAgrawalTDel CoreMGHunterWJIIIAgrawalDKDecreased expression of vitamin D receptors in neointimal lesions following coronary artery angioplasty in atherosclerotic swine. PLoS ONE201278e42789.
33.
WasseHHuangRNaqviNSmithEWangDHusainAInflammation, oxidation and venous neointimal hyperplasia precede vascular injury from AVF creation in CKD patients. J Vasc Access2012132168–174
AlvarezJWasseHTangprichaVVitamin D supplementation in pre-dialysis chronic kidney disease: a systematic review. Dermatoendocrinol201242118–127
36.
LeeTTindniARoy-ChaudhuryPImproved cumulative survival in fistulas requiring surgical interventions to promote fistula maturation compared with endovascular interventions. Semin Dial2012Mar9
37.
BaderoOJSalifuMOWasseHWorkJFrequency of swing-segment stenosis in referred dialysis patients with angiographically documented lesions. Am J Kidney Dis200851193–98
38.
AllonMRobbinMLIncreasing arteriovenous fistulas in hemodialysis patients: problems and solutions. Kidney Int20026241109–1124
39.
WongVWardRTaylorJSelvakumarSHowTVBakranAFactors associated with early failure of arteriovenous fistulae for haemodialysis access. Eur J Vasc Endovasc Surg1996122207–213
40.
KortenEToonderIMSchramaYCHopWCvan der HamACWittensCHDialysis fistulae patency and preoperative diameter ultrasound measurements. Eur J Vasc Endovasc Surg2007334467–471
41.
TareMEmmettSJColemanHAVitamin D insufficiency is associated with impaired vascular endothelial and smooth muscle function and hypertension in young rats. J Physiol2011589Pt 194777–4786
42.
HarrisRAPedersen-WhiteJGuoDHVitamin D3 supplementation for 16 weeks improves flow-mediated dilation in overweight African-American adults. Am J Hypertens2011245557–562
43.
GalisZSKhatriJJMatrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res2002903251–262
44.
MagidRMurphyTJGalisZSExpression of matrix metalloproteinase-9 in endothelial cells is differentially regulated by shear stress. Role of c-Myc. J Biol Chem20032783532994–32999
45.
ChangCJKoYSKoPJThrombosed arteriovenous fistula for hemodialysis access is characterized by a marked inflammatory activity. Kidney Int20056831312–1319
46.
WasseHCardarelliFDe StaerckeCHooperCVeledarEGuessousI25-Hydroxyvitamin D concentration is inversely associated with serum MMP-9 in a cross-sectional study of African American ESRD patients. BMC Nephrol201112124.
47.
AiharaKAzumaHAkaikeMDisruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice. J Biol Chem20042793435798–35802
48.
BeerTMVennerPMRyanCWHigh dose calcitriol may reduce thrombosis in cancer patients. Br J Haematol20061353392–394
